A database of FDA approved therapeutic peptides and proteins
ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1372 | Th1055 | Follitropin beta | A Chain: APDVQDCPECT Full view | 204 | Ib | Hormonal disorders | Follistim AQ | Merck | Sterile aqueous solution | Subcutaneous or Intramuscular administration | Fertility Agents | Follicle-stimulating hormone receptor |
1439 | Th1077 | Urofollitropin | Alpha chain:APDVQDCP Full view | 203 | Ib | Hormonal | BRAVELLE | Ferring Pharmaceuticals Inc. | Sterile, lyophilized powder used after reconstitution with sterile 0.9% Sodium Chloride Injection | Intramuscular and Subcutaneous administration | Fertility Agents | Glutamate carboxypeptidase 2 |
1440 | Th1077 | Urofollitropin | Alpha chain:APDVQDCP Full view | 203 | Ib | Hormonal | Metrodin | N.A. | Sterile, lypholized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Intramuscular injection. | Fertility Agents | Glutamate carboxypeptidase 2 |
1441 | Th1077 | Urofollitropin | Alpha chain:APDVQDCP Full view | 203 | Ib | Hormonal | Fertinex | N.A. | Sterile, lyophilized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Subcutaneous injection. | Fertility Agents | Glutamate carboxypeptidase 2 |
1442 | Th1078 | Efalizumab | Light Chain:DIQMTQSP Full view | 229 | IIa | Immunological | RAPTIVA | Genentech, Inc. | Sterile, white to off-white, lyophilized powder in single-use glass vials | Subcutaneous injection. | Immunosuppressive Agents | Iduronic acid |
1447 | Th1080 | Choriogonadotropin Alfa | Alpha chain: APDVQDC Full view | 237 | Ib | Hormonal | Choriogonadotropin alfa | Emd serono inc, Ferring pharmaceuticals inc, App pharmaceuticals llc, Bel mar laboratories inc, Bris | N.A. | N.A. | Fertility Agents and Gonadotropins | Integrin alpha-L, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
1455 | Th1085 | Agalsidase Beta | LDNGLARTPTMGWLHWERFM Full view | 398 | Ia | Metabolic | Fabrazyme | Genzyme Corp | Sterile, nonpyrogenic, white to off-white, lyophilized cake or powder for reconstitution with Sterile Water for Injection | N.A. | Enzyme Replacement Agents | N.A. |
1468 | Th1091 | Bevacizumab | DIQMTQSPSSLSASVGDRVT Full view | 214 | IIa | Cardiac | Avastin | Genentech | Slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion | Intravenous infusion | Angiogenesis Inhibitors | Interleukin-2 receptor subunit alpha,Interleukin-2 receptor subunit beta,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
1495 | Th1102 | Abatacept | MHVAQPAVVLASSRGIASFV Full view | 357 | IIa | Immunological | ORENCIA | Bristol-Myers Squibb | Lyophilized powder, supplied as a sterile, white, preservative-free, lyophilized powder for intravenous administration | Intravenous infusion and Subcutaneous injection | Antirheumatic Agents and Immunosuppressive Agents | T-lymphocyte activation antigen CD80,T-lymphocyte activation antigen CD86 |
1596 | Th1126 | Belatacept | MHVAQPAVVLASSRGIASFV Full view | 357 | IIa | Immunological | Nulojix | Bristol-Myers Squibb | Sterile, white or off-white lyophilized powder | Intravenous injection | Antirheumatic Agents and Immunosuppressive Agents | T-lymphocyte activation antigen CD86,T-lymphocyte activation antigen CD80 |
1621 | Th1134 | Asparaginase Erwinia Chrysanthemi | ADKLPNIVILATGGTIAGSA Full view | 327 | Ic | Hormonal | Erwinaze | EUSA Pharma | Sterile, lyophilized, white powder in vials. | Intramuscular injection | Enzymes | N.A. |
1622 | Th1135 | Ocriplasmin | Truncated heavy chai Full view | 251 | Ic | Eye Disorder | Jetrea | ThromboGenics NV | Sterile, clear and colorless solution with no preservatives | Intravitreal injection | Ophthalmics | Fibronectin,Alpha-2-macroglobulin,Alpha-2-antiplasmin |
1623 | Th1136 | Glucarpidase | ALAQKRDNVLFQAATDEQPA Full view | 393 | Ic | Hormonal | Voraxaze | BTG International | Sterile, preservative-free, white lyophilized powder in single-use vials | Intravenous injection | Enzymes | Methotrexate |
1640 | Th1145 | Romiplostim | Thrombopoietin recep Full view | 269 | Ib | Immunologcal | Nplate | Amgen | Sterile, preservative-free, lyophilized, solid white powder | Subcutaneous injection | Colony-Stimulating Factors and Thrombopoietic Agents | N.A. |
1662 | Th1154 | OspA lipoprotein | MKKYLLGIGLILALIACKQN Full view | 272 | IIIa | Infectious | Lymerix | SmithKline Beecham | Sterile suspension | Intramuscular Injection | Vaccines | Toll-like receptor 2 |
1663 | Th1155 | Urokinase | KPSSPPEELKFQCGQKTLRP Full view | 276 | Ib | Haemetological | Kinlytic | N.A. | Sterile lyophilized white powder | Intravenous infusion | N.A. | Plasminogen,Urokinase plasminogen activator surface receptor, Urokinase-type plasminogen activator, Tissue-type plasminogen activator, Plasminogen activator inhibitor 1, 2, Plasma serine protease inhibitor, Low-density lipoprotein receptor-related protein 2, Suppressor of tumorigenicity 14 protein, Nidogen-1 |
1729 | Th1176 | Dulaglutide | HGEGTFTSDVSSYLEEQAAK Full view | 275 | Ib | Metabolic Disorders | Trulicity | Eli Lilly and Company | Solution, Injection | Subcutaneous | Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins | Glucagon-like peptide 1 receptor |
1730 | Th1176 | Dulaglutide | HGEGTFTSDVSSYLEEQAAK Full view | 275 | Ib | Metabolic Disorders | Trulicity | Eli Lilly Canada Inc | Solution | Subcutaneous | Hypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins | Glucagon-like peptide 1 receptor |
1803 | Th1197 | Sebelipase alfa | SGGKLTAVDPETNMNVSEII Full view | 378 | Ia | Genetic Disorders | Kanuma | Alexion Pharmaceuticals, Inc. | Aqueous Solution | Intravenous infusion | Enzymes | NA |
1833 | Th1223 | Chorionic Gonadotropin (Human) | Alpha Chain: APDVQDC Full view | 237 | Ia | Hormonal Disorders | Ovidrel | Emd Serono | Injection, solution | Subcutaneous | Hormones | Lutropin-choriogonadotropic hormone receptor |
1834 | Th1223 | Chorionic Gonadotropin (Human) | Alpha Chain: APDVQDC Full view | 237 | Ia | Hormonal Disorders | Pregnyl | Physicians Total Care, Inc. | Injection, Solution | Intramuscular, Subcutaneous | Hormones | Lutropin-choriogonadotropic hormone receptor |
1835 | Th1224 | Chorionic Gonadotropin (Recombinant) | Alpha chain : APDVQD Full view | 237 | Ia | Hormonal Disorders | Ovitrelle | Merck Serono Europe Limited | powder and solvent to be made up into a solution | Subcutaneous | Hormones | Lutropin-choriogonadotropic hormone receptor, Follicle-stimulating hormone receptor |
1845 | Th1233 | Pegloticase | TYKKNDEVEFVRTGYGKDMI Full view | 298 | Ib | Osteological Disorders | Pegloticase (Krystexxa) | NA | Solid | Intravenous | Enzymes | Uric acid |